Conditions: Diabetes Mellitus, Type 2
Allocation:  | Intervention model: PARALLEL
Enrollment: 495
Healthy volunteers: no

Brief summary:
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM with insufficient glycemic control. In addition, there will be an open-label treatment arm with sitagliptin (JanuviaTM) as add-on therapy to metformin.

Detailed description:

Arms:

Interventions: intervention 1: BI 10773 intervention 2: placebo intervention 3: sitagliptin
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: